Related Experiment Video
Updated: Oct 24, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A
Qing Zhou1, Chong-Rui Xu1, Ying Cheng2
1Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Abstract:
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung cancer (NSCLC). This phase 3 study investigated the efficacy and safety of an erlotinib plus bevacizumab regimen in untreated patients with advanced NSCLC. In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinib only (n = 154). Progression-free survival (PFS) was 17.9 months (95% confidence interval [CI], 15.2-19.9) for bevacizumab plus erlotinib and 11.2 months (95% CI, 9.7-13.8) for erlotinib only (hazard ratio [HR] = 0.55; 95% CI, 0.41-0.73; p < 0.001). A brain metastases subgroup treated with bevacizumab plus erlotinib also showed improved PFS (HR = 0.48; 95% CI, 0.27-0.84; p = 0.008). Grade ≥3 treatment-related adverse events occurred in 86 (54.8%) and 40 (26.1%) patients, respectively. Bevacizumab plus erlotinib significantly improved PFS in patients with untreated metastatic EGFR-mutated NSCLC, including those with brain metastases at baseline.
Insights
Adding bevacizumab to erlotinib significantly improved progression-free survival for advanced non-small cell lung cancer (NSCLC) patients. This combination therapy also benefited patients with brain metastases, showing enhanced efficacy in delaying disease progression.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Advanced non-small cell lung cancer (NSCLC) often develops therapeutic resistance.
- Targeting both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways is a strategy to overcome resistance.
Purpose of the Study:
- To evaluate the efficacy and safety of combining erlotinib with bevacizumab in previously untreated advanced NSCLC patients.
- To assess the impact of dual EGFR and VEGF pathway inhibition on progression-free survival (PFS).
Main Methods:
- A phase 3 clinical trial involving 311 untreated advanced NSCLC patients.
- Patients were randomized to receive either bevacizumab plus erlotinib or erlotinib alone.
- Progression-free survival (PFS) and treatment-related adverse events were primary endpoints.
Main Results:
- The combination of bevacizumab and erlotinib resulted in a median PFS of 17.9 months, compared to 11.2 months for erlotinib alone (HR=0.55, p<0.001).
- A significant PFS improvement was observed in the subgroup with brain metastases (HR=0.48, p=0.008).
- Grade ≥3 treatment-related adverse events were higher in the combination arm (54.8%) versus erlotinib alone (26.1%).
Conclusions:
- Bevacizumab plus erlotinib significantly enhances PFS in untreated advanced NSCLC, including patients with brain metastases.
- Dual inhibition of EGFR and VEGF pathways offers a promising therapeutic strategy for advanced NSCLC.
- Careful monitoring for adverse events is necessary when using this combination regimen.
More Related Videos
09:24Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
Published on: September 18, 2019
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019